Device-based neuromodulation therapies may offer a viable alternative for patients with depression who do not achieve adequate response to SSRIs.
Patient Receives Depression Treatment Using neurocare’s Apollo TMS System A patient undergoing Transcranial Magnetic Stimulation (TMS) therapy for depression with neurocare’s Apollo TMS System in a ...
Patient Receives Depression Treatment Using neurocare’s Apollo TMS System A patient undergoing Transcranial Magnetic Stimulation (TMS) therapy for depression with neurocare’s Apollo TMS System in a ...
A peer-reviewed case study published in the journal Transcranial Magnetic Stimulation reports that an accelerated transcranial magnetic stimulation (aTMS) protocol was associated with significant ...
EDAP Announces Corporate Name Change to FocalTherics to Reflect Exclusive Focus on High-Growth Robotic Focal Therapy Company will Begin Trading Under New Ticker Symbol ...
Focal One to Present at Jefferies 2026 Global Healthcare Conference . Company to Present and Host 1x1 Investor Meetings on ...
AUSTIN, Texas - May 14, 2026 - EDAP TMS S.A. (Nasdaq: EDAP) today announced that it has entered into a letter of intent with Telix Pharmaceuticals Limited ("Telix") ...
The Dáil Public Accounts Committee has heard that a €50 million write-off by Iarnród Éireann of a failed IT project is an ...
EDAP Reports Strong Financial Results with Record First Quarter HIFU Revenue. Seventh Consecutive Quarter of Year-Over-Year HIFU Revenue Growth.
Brainsway () has held its Q1 earnings call. Read on for the main highlights of the call. Claim 55% Off TipRanks. Unlock hedge fund-level data and powerful investing tools for smar ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results